Ventra Sciences Review & Prices

A research blend combining a short-acting GHRH analogue with a ghrelin-receptor agonist to study pulsatile growth-hormone signaling.

A synthetic tetrapeptide studied in aging, telomerase, circadian and cellular-biology research. Human evidence remains limited.

If you've ever seen a blue-tinted skincare serum, you've already met GHK-Cu. It's a copper-carrying tripeptide that was first pulled out of human blood plasma back in 1973, and it's been sitting in cosmetics for decades. What's newer is its life as a research peptide: vials of it, and blends like Glow and Klow that put it alongside BPC-157 and TB-500 . I'll say upfront that GHK-Cu is a bit unusual in this catalog. It has a long research history, and the skin-care version is a mainstream cosmetic ingredient. But no GHK-Cu drug is approved by the FDA, and the injectable side is much less studied than the creams. On Peptide Grading , we line up the research-labeled listings, with vendors, sizes, price per mg, and COAs , so you can see the differences. A listing isn't a recommendation to use it.

A naturally occurring tripeptide and major intracellular antioxidant involved in redox balance, detoxification and cellular defense.

IGF-1 LR3, also called Long R3 IGF-1 , is a recombinant analogue of human insulin-like growth factor 1. Its structure combines a 13-amino-acid N-terminal extension with an arginine substitution at position 3 of the mature IGF-1 sequence. These changes were designed to alter how the molecule interacts with IGF-binding proteins while retaining activity at the IGF-1 receptor. Research has therefore used IGF-1 LR3 as a tool for studying IGF signaling, cell growth, protein synthesis, and growth-factor biology.

Ipamorelin is a five-amino-acid peptide that switches on the ghrelin receptor and makes the pituitary release growth hormone. Novo Nordisk researchers built it in the 1990s, and what made it interesting was how narrow its effect looked. Older compounds in the same family pushed up other hormones too. Ipamorelin mostly didn't. It has no approved use anywhere. A Phase 2 trial in the early 2000s tried it for a bowel problem after surgery, and it didn't work well enough to continue. So what's left is mostly lab and animal data, and the research-labeled vials that vendors sell. On Peptide Grading , we list those vials with vendors, sizes, price per mg, and COA documents in one place, so you can compare them without hunting through tabs.

Melanotan II is a lab-made peptide modeled on α-melanocyte-stimulating hormone (α-MSH), the natural hormone that tells your skin to make pigment. Researchers built it to understand how the melanocortin receptor system works, especially the pathways behind melanin production. It's tempting to file MT-II under "tanning peptides," but that undersells it. It acts on several receptors, not just one, and that's why human studies have looked at both skin pigmentation and erectile function. The case reports that followed raised some real safety questions. On Peptide Grading , we track MT-II research listings in one place: vendors, quantities, prices, shipping details, and certificate of analysis (COA) documents, so you don't have to open ten tabs to compare them.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by a short open reading frame in the mitochondrial 12S rRNA region. Peptide Grading tracks MOTS-c vendors, quantities, prices, shipping details, and COA information to make research-product listings easier to compare.

NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring cellular coenzyme involved in energy metabolism, redox reactions, and several signaling pathways. It is found throughout living cells and continuously shifts between its oxidized NAD+ and reduced NADH forms. Unlike peptide compounds, NAD+ is a dinucleotide, making its research profile quite different from synthetic peptide products.

Retatrutide is an experimental once-weekly injection from Eli Lilly (internal code LY3437943). It's a single molecule that activates three receptors: GIP, GLP-1, and glucagon. Tirzepatide covers the first two, and retatrutide adds the third. It isn't approved anywhere, for anything. Lilly has said it plans to file with the FDA in the first quarter of 2027. On Peptide Grading , we list the research-labeled vials with sizes, price per mg, and COAs side by side. Being listed there isn't an endorsement, and those vials aren't Lilly's product.